Emerald Advisers, LLC Celldex Therapeutics, Inc. Transaction History
Emerald Advisers, LLC
- $2.41 Billion
- Q3 2024
A detailed history of Emerald Advisers, LLC transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Emerald Advisers, LLC holds 456,202 shares of CLDX stock, worth $12.7 Million. This represents 0.64% of its overall portfolio holdings.
Number of Shares
456,202
Previous 198,429
129.91%
Holding current value
$12.7 Million
Previous $7.34 Million
111.04%
% of portfolio
0.64%
Previous 0.33%
Shares
3 transactions
Others Institutions Holding CLDX
# of Institutions
207Shares Held
67.3MCall Options Held
1.69MPut Options Held
980K-
Wellington Management Group LLP Boston, MA9.24MShares$258 Million0.06% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$131 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.87MShares$108 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ3.46MShares$96.5 Million9.64% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.33MShares$92.9 Million1.99% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1.3B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...